It can feel discouraging to see a competitor reach funding faster, especially when your therapy demonstrates equal or greater innovation. The difference often has less to do with the product itself and more to do with how effectively its value is communicated and championed within the political system.
Every therapy entering the process is backed by strong clinical evidence. If you are relying on your data to get your therapy funded, you will likely be waiting for a long time. What often accelerates one therapy over another is how visible and relatable its case becomes. Competitors who move ahead are usually those who:
Data proves safety and effectiveness, but stories create momentum. Decision-makers hear countless numbers every day. What stands out are the human consequences of delay: the patient who cannot return to work, the family bearing ongoing costs, or the clinician who cannot offer a better solution. Competitors who make these stories visible often create the urgency needed to move forward.
Faster outcomes are rarely the result of one conversation. They come from a network of champions. There are patient groups, clinicians, and parliamentarians who consistently press the case. This chorus of voices becomes increasingly difficult to tune out, which signals to ministers and departments that the issue deserves priority.
If a competitor moved faster, it is unlikely that their product was more valuable. It is more often because their advocacy strategy ensured the right people understood that value and felt compelled to act. That same approach can be applied to your therapy.
By combining evidence with advocacy and pairing data with compelling stories, your innovation can move forward with greater momentum. Progress is shaped not only by what a therapy can do, but by how clearly its benefits are understood and championed in the political landscape.
